Finanzen von WAVE Life Sciences Ltd (WVE)WVEWAVE Life Sciences Ltd

Evaluating the bottom line, Wave Life Sciences, Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3248.33%, while the net margin is -3052.60%. These profitability ratios, combined with a Return on Equity (ROE) of -68.31%, provide a clear picture of how effectively WVE converts its operational activities into shareholder value.

In the context of the broader market, WVE competes directly with industry leaders such as EPRX and CADL. With a market capitalization of $674.52M, it holds a significant position in the sector. When comparing efficiency, WVE's gross margin of 100.00% stands against EPRX's N/A and CADL's N/A. Such benchmarking helps identify whether Wave Life Sciences, Inc is trading at a premium or discount relative to its financial performance.

WAVE Life Sciences has shown declining financial performance with total revenue dropping from $8.7 million in Q2 2025 to $2.3 million in Q2 2026, alongside increasing net losses.